Trial Profile
Non-interventional study concerning efficacy and safety of the intraperitoneal therapy with Removab(R) under routine practice conditions: Ambulant Catumaxomab Therapy: ACT
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Catumaxomab (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- Acronyms ACT
- Sponsors Neovii Biotech
- 07 Sep 2011 New trial record